Title : Erlotinib overcomes paclitaxel-resistant cancer stem cells by blocking the EGFR-CREB/GRĪ²-IL-6 axis in MUC1-positive cervical cancer.

Pub. Date : 2019 Nov 26

PMID : 31772161






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In this context, MUC1 induces CSCs enrichment in paclitaxel-resistant cells via activation of EGFR, which directly enhances IL-6 transcription through cAMP response element-binding protein (CREB) and glucocorticoid receptor beta (GRbeta). Paclitaxel interleukin 6 Homo sapiens
2 Collectively, our work has demonstrated that the MUC1-EGFR-CREB/GRbeta axis stimulates IL-6 expression to induce CSCs enrichment and importantly, this effect can be abrogated by erlotinib, uncovering a novel strategy to treat paclitaxel-resistant cervical cancer. Paclitaxel interleukin 6 Homo sapiens